Immune therapy doubles lung cancer survival rate

April 17, 2018
New drugs that trigger a patient’s immune system to kill malignant cells can greatly improve the survival rate of people with the most common type of lung cancer, a new study found. The study, published in the New England Journal of Medicine, found that patients treated with the checkpoint inhibitor pembrolizumab, or Keytruda,...

Related Videos

Lung Cancer Patients Fair Better with Immune Therapy
 ▶ Wochit News - on April 16, 2018  00:45

Immunotherapy Advances For Lung Cancer Patients
 ▶ Wochit News - on April 16, 2018  00:32

New studies show hope in fighting lung cancer
 ▶ CBS News - on April 17, 2018  03:52

Merck Expands Lead in Lung Cancer Therapy
 ▶ Bloomberg Global Business - on April 16, 2018  02:26

You might like